<DOC>
	<DOCNO>NCT00366366</DOCNO>
	<brief_summary>This study assess immunogenicity safety two vaccination regimen employ either GSK Biologicals ' combined DTPa-HBV-IPV/Hib vaccine DTPa-IPV/Hib vaccine . In two group , infant receive DTPa-IPV/Hib vaccine 3 4 month age , first 2 dos primary vaccination course . At 5 month age , receive either DTPa-IPV/Hib vaccine co-administered HBV vaccine dose DTPa-HBV-IPV/Hib vaccine 3rd dose . Infants two group previously receive 2 dos HBV vaccine birth 1 month age .</brief_summary>
	<brief_title>To Evaluate Immunogenicity &amp; Safety GSK Bio 's DTPa-HBV-IPV/Hib ( Mixed Vaccine ) DTPa-IPV/Hib + HBV Vaccines</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<criteria>A male female infant age 11 17 week . Written inform consent obtain parent guardian subject . Free obvious health problem establish clinical examination enter study . Hepatitis B vaccine birth one month age . Previous vaccination measles , mumps , rubella and/or varicella . Use investigational nonregistered drug vaccine study vaccine within 30 day precede first dose study vaccine , plan use study period . A family history congenital hereditary immunodeficiency . Any confirm suspected immunosuppressive immunodeficient condition , include HIV infection . Major congenital defect . History allergic disease reaction likely exacerbate component vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>11 Weeks</minimum_age>
	<maximum_age>17 Weeks</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>